Jim Simons C4 Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$4.05 - $8.1 $690,930 - $1.38 Million	-170,600 Reduced 42.04%	235,200 $1.09 Million
Q1 2024 May 13, 2024	SELL	$5.3 - $11.0 $100,170 - $207,900	-18,900 Reduced 4.45%	405,800 $3.32 Million
Q4 2023 Feb 13, 2024	BUY	$1.18 - $6.03 $78,720 - $402,273	66,712 Added 18.64%	424,700 $2.4 Million
Q3 2023 Nov 14, 2023	SELL	$1.81 - $3.89 $287,627 - $618,159	-158,910 Reduced 30.74%	357,988 $666,000
Q2 2023 Aug 11, 2023	BUY	$2.75 - $3.77 $524,749 - $719,383	190,818 Added 58.52%	516,898 $1.42 Million
Q1 2023 May 12, 2023	BUY	$3.1 - $9.02 $910,098 - $2.65 Million	293,580 Added 903.32%	326,080 $1.02 Million
Q4 2022 Feb 13, 2023	SELL	$5.42 - $10.24 $164,226 - $310,272	-30,300 Reduced 48.25%	32,500 $192,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $411,938 - $655,101	51,300 Added 446.09%	62,800 $551,000
Q2 2022 Aug 12, 2022	BUY	$5.06 - $26.46 $58,189 - $304,290	11,500 New	11,500 $87,000
Q1 2022 May 13, 2022	SELL	$19.99 - $33.23 $625,687 - $1.04 Million	-31,300 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$29.39 - $46.86 $919,907 - $1.47 Million	31,300 New	31,300 $1.01 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $178M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.